Inner-City Asthma Consortium

Clinical Studies

NIAID supports research to address the disproportionate public health burden of asthma in inner-city populations. NIAID funds the Inner-City Asthma Consortium (ICAC), to conduct research focused on understanding how the environment, allergens, and genetics interact with the body’s immune system to cause asthma and aggravate its symptoms.

The following ICAC clinical studies are recruiting participants. The links lead to full eligibility criteria, study site locations, and contact information:

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (MUPPITS-2) (NCT03292588)
The purpose of this study is to see if treatment with a medication called mepolizumab, given along with standard asthma care, makes children less likely to have asthma attacks. Children ages 6-17 years who received an asthma diagnosis by a clinician may be eligible to participate.

Cockroach Immunotherapy in Children and Adolescents (CRITICAL) (NCT03541187)
Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. The primary objective of this study is to determine if asthma severity can be improved by cockroach subcutaneous immunotherapy treatment.

Registry for Asthma Characterization and Recruitment 2 (RACR2) (NCT02513264)
There is a need for people to take part in research studies to learn more about diseases and how to treat them. RACR2 will create a database of participants ages 1-55 years with asthma and nasal allergies, or risk factors for these conditions, who are potentially eligible for future ICAC trials.

Read more about the NIAID role in asthma research.

Visit the NIH website to learn about the importance of children in clinical studies.

Content last reviewed on September 10, 2018